Cellectar Biosciences Inc. received a patent covering the method of use for CLR 1603 to treat breast, lung, colorectal and prostate cancers as well as associated cancer stem cells.
The patent protection will last through the end of 2035.
Cellectar Biosciences receives patent protection for cancer drug
Gauging Supply Chain Risk In Volatile Times
Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals
The Future of Risk Management Digitization in Credit Risk Management
Climate Credit Analytics: Diving into the model
Cellectar Biosciences receives patent protection for cancer drug
- Author Muhammad Ahmer Gul Khan
- Theme Healthcare & Pharmaceuticals